

# Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

## PRECISESADS

RRID:SCR\_003882

Type: Tool

---

### Proper Citation

PRECISESADS (RRID:SCR\_003882)

---

### Resource Information

**URL:** <http://www.precisesads.eu/>

**Proper Citation:** PRECISESADS (RRID:SCR\_003882)

**Description:** A project that will study 2,500 people with various systemic autoimmune diseases (SADs), gathering data on the molecular causes of their disease as well as their clinical symptoms, enabling them to pave the way for a new classification of these diseases. The goal is to use OMICs and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Results will be shared to deliver a new molecular taxonomy of systemic autoimmune diseases. In order to achieve this, PRECISEADS is informing on a regular basis on the project implementation and results, and involving stakeholders from Europe in its activities in order to broaden the project impact and increase opportunities for cooperation.

**Abbreviations:** PRECISESADS

**Synonyms:** PRECISESADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases

**Resource Type:** organization

**Keywords:** biomarker, diagnostic, basic research, clinical, genomics, transcriptomics, epigenomics, flow cytometry, cellular separations, pre-clinical model, proteomics, metabolomics, serology, tissue, taxonomy, imaging, biosample, sample collection, biobanking, blood, urine

**Funding:** Innovative Medicines Initiative ;  
EFPIA

**Resource Name:** PRECISESADS

**Resource ID:** SCR\_003882

**Alternate IDs:** nlx\_158209

**Record Creation Time:** 20220129T080221+0000

**Record Last Update:** 20260905T132510+0000

---

## Ratings and Alerts

No rating or validation information has been found for PRECISESADS.

No alerts have been found for PRECISESADS.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 19 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

E Silva-Saffar S, et al. (2026) The SjD Map: an interactive pathway tour into Sjögren's disease signalling mechanisms. NPJ systems biology and applications, 12(1).

Bézier C, et al. (2026) GEDO: topology-based inference of gene module activity in Sjögren's disease. Briefings in bioinformatics, 27(3).

Iakovliev A, et al. (2025) Discovery of core genes for systemic lupus erythematosus via genome-wide aggregated trans-effects analysis. Genes and immunity, 26(5), 497.

Dans-Caballero S, et al. (2025) Systemic sclerosis: bridging clinical and molecular insights: results from the PRECISESADS study. Journal of translational medicine, 24(1), 17.

Toro-Domínguez D, et al. (2025) Benchmarking single-sample gene set scoring methods for application in precision medicine. Briefings in bioinformatics, 26(6).

Lindblom J, et al. (2025) Dysregulation of innate and adaptive lymphoid immunity may have implications for symptom attribution and predict responses to targeted therapies in neuropsychiatric systemic lupus erythematosus. Journal of translational autoimmunity, 11, 100296.

Castellini-Pérez O, et al. (2024) Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants. NPJ genomic medicine, 9(1), 38.

Lindblom J, et al. (2023) Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus. Frontiers in immunology, 14, 1257085.

Ortega-Ferreira C, et al. (2023) Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis. *Nature communications*, 14(1), 5291.

Barturen G, et al. (2022) Whole blood DNA methylation analysis reveals respiratory environmental traits involved in COVID-19 severity following SARS-CoV-2 infection. *Nature communications*, 13(1), 4597.

Foulquier N, et al. (2022) Machine Learning for the Identification of a Common Signature for Anti-SSA/Ro 60 Antibody Expression Across Autoimmune Diseases. *Arthritis & rheumatology* (Hoboken, N.J.), 74(10), 1706.

Soret P, et al. (2021) A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. *Nature communications*, 12(1), 3523.

Marziale A, et al. (2020) Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases. *Journal of autoimmunity*, 115, 102524.

Le Lann L, et al. (2020) Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. *Scientific reports*, 10(1), 11567.

Fernández-Ochoa Á, et al. (2020) A Case Report of Switching from Specific Vendor-Based to R-Based Pipelines for Untargeted LC-MS Metabolomics. *Metabolites*, 10(1).

Thiagarajan D, et al. (2020) IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. *Scientific reports*, 10(1), 11010.

Carnero-Montoro E, et al. (2019) Epigenome-Wide Comparative Study Reveals Key Differences Between Mixed Connective Tissue Disease and Related Systemic Autoimmune Diseases. *Frontiers in immunology*, 10, 1880.

Cossu M, et al. (2018) Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective. *Clinical reviews in allergy & immunology*, 55(3), 312.

Schuhmacher A, et al. (2018) Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? *Journal of translational medicine*, 16(1), 119.